GLP-1 Bridge GLP-1 Bridge Program: What Medicare Patients Need to Know

A new temporary Medicare program is now underway that many patients are hearing about—the GLP-1 Bridge Program. While it offers potential access to certain medications, it is important to understand what it is, what it is not, and why it IS NOT as simple as it sounds.

What is the GLP-1 Bridge Program?

The GLP-1 Bridge Program is a temporary pilot program created by the Centers for Medicare & Medicaid Services (CMS). It began on July 1, 2026 and is scheduled to end on December 31, 2027.

The intent of this program is to “bridge” access to GLP-1 medications for certain Medicare beneficiaries while Medicare Part D prescription drug plans evolve to provide more consistent long-term coverage in the future.

What medications are included?

The program currently includes:

• Foundayo (a newer GLP-1 tablet that can be taken with or without food)

• Wegovy (available as: • a weekly injection • a daily tablet that must be taken first thing in the morning with a small amount of water, with no food, drink, or medications for 30 minutes)

• A specific version of Zepbound (weekly injectable using a multidose KwikPen, which requires separate pen needles for each injection)

  
  

Important: Some patients may need to switch products or delivery systems to qualify, especially if currently paying directly through a manufacturer-based discount pharmacy program.

Who qualifies—and why it’s complicated

This program does not simply follow FDA-approved uses of GLP-1 medications. Instead, it uses its own set of Medicare-specific criteria, which are confusing and restrictive.

Even if a medication is FDA-approved for your condition, you may not qualify for the Bridge Program.

In addition:

• A separate Medicare-run preauthorization process is required

• This process is often administratively complex

• Approval is not guaranteed, even for medically appropriate patients

This creates a situation where patients often expect a smooth process—but in reality, it is almost always time-consuming and challenging for both patients and especially the prescribing clinicians, mostly primary care teams.

Who is NOT eligible?

Certain Medicare beneficiaries are excluded entirely, including:

• Cost contract plans

• PACE programs (Programs of All-Inclusive Care for the Elderly)

• Some private fee-for-service plans

• Traditional Medicare without Part D

• Medicare Advantage plans without prescription drug coverage

  
  

Additional important limitations

• If your Medicare Part D plan already covers a GLP-1 medication (even at a high out of pocket cost to you), you are NOT eligible for the Bridge Program

• If you qualify for a GLP-1 medication due to another FDA-approved condition (such as Type 2 Diabetes, Obstructive Sleep Apnea, or MASH/fatty liver disease), you must obtain it through your Part D plan—not the discounted Bridge Program price.

• If your Part D plan denies coverage for those conditions, you still do NOT qualify for the Bridge Program

• Costs paid through the Bridge Program do NOT count toward deductibles or out-of-pocket maximums

  
  

Why this matters

This program introduces a new pathway—but not a simple one.

Many of the rules:

• Are not based on standard clinical or FDA frameworks

• Exclude patients for non-clinical reasons

• Create significant administrative work for care teams

  
  

As a result, both patients and clinicians are navigating a system that is still evolving and difficult to interpret or fully understand.

A request for patience and partnership

Primary care teams are working hard to understand and implement this program appropriately. However, the reality is that:

• The rules are complex and often arbitrary

• The approval process is separate and burdensome

• Many decisions are outside the control of your clinician

  
  

We ask for your patience as we work through these challenges together. Our goal remains the same: to provide the best, most appropriate care possible while navigating a rapidly changing insurance landscape.

Looking ahead

The hope is that by the time this program ends in December 2027, Medicare Part D plans will offer more consistent, transparent, and clinically aligned coverage for GLP-1 medications.

Until then, this Bridge Program represents a transitional step—not a complete solution.

Sincerely,

Winslow Williams Murdoch,

MD Family Medicine 1450 E Boot Rd,

Ste 300A West Chester,

PA 19380 Phone: 610-692-4700 

Fax: 610-692-6444